Editorial: New insights into innate immune cell-based immunotherapies in cancer

Editorial: New insights into innate immune cell-based immunotherapies in cancer

Bibliographic Details
Main Authors:	Anne Caignard, Mary Poupot-Marsan, Virginie Lafont, Daniela Wesch, Chiara Porta
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Series:	Frontiers in Immunology
Subjects:	macrophages & neutrophils NK cells γδ T cells CAR-NK bispecific antibodies patient avatars
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1401665/full

Similar Items

NK Cell-Based Immunotherapy in Colorectal Cancer
by: Mariella Della Chiesa, et al.
Published: (2022-06-01)

Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future
by: Fabio Morandi, et al.
Published: (2021-01-01)

Emerging Trends in Immunotherapy for Cancer
by: Alok K. Mishra, et al.
Published: (2022-09-01)

Natural killer cells: a promising immunotherapy for cancer
by: Junfeng Chu, et al.
Published: (2022-05-01)

Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy
by: Massimo Fantini, et al.
Published: (2023-11-01)

DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy
by: Loredana Cifaldi, et al.
Published: (2023-06-01)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
by: Tian Huan, et al.
Published: (2023-08-01)

Osteoclasts and Probiotics Mediate Significant Expansion, Functional Activation and Supercharging in NK, γδ T, and CD3+ T Cells: Use in Cancer Immunotherapy
by: Kawaljit Kaur, et al.
Published: (2024-01-01)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
by: Xinyu Wu, et al.
Published: (2022-12-01)

Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells
by: Fabio Morandi, et al.
Published: (2020-07-01)

Editorial: Women in NK and innate lymphoid cell biology
by: Alessandra Zingoni, et al.
Published: (2023-02-01)

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
by: Antonio Tapia-Galisteo, et al.
Published: (2023-07-01)

The prospect of genetically engineering natural killer cells for cancer immunotherapy
by: Angie Yu Ching Poon, et al.
Published: (2022-12-01)

Editorial: Engineered Targeted Cancer Immunotherapies
by: Massimo Fantini, et al.
Published: (2022-07-01)

Intrinsic Immune Response of HBV/HDV-Infected Cells and Corresponding Innate (Like) Immune Cell Activation
by: Christopher Groth, et al.
Published: (2024-11-01)

Harnessing natural killer cells to develop next‐generation cellular immunotherapy
by: Siyao Liu, et al.
Published: (2022-12-01)

Prospects for NK-based immunotherapy of chronic HBV infection
by: Xiaomeng Jin, et al.
Published: (2022-12-01)

A modifiable universal cotinine-chimeric antigen system of NK cells with multiple targets
by: Hee Young Kang, et al.
Published: (2023-01-01)

NK cell-based tumor immunotherapy
by: Hao Zhang, et al.
Published: (2024-01-01)

Development of BCMA-Targeted Bispecific Natural Killer Cell Engagers for Multiple Myeloma Treatment
by: Minchuan Zhang, et al.
Published: (2024-11-01)

Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies
by: Massimo Giuliani, et al.
Published: (2020-06-01)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
by: Xiaopeng Tian, et al.
Published: (2023-04-01)

CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
by: Zeljko Todorovic, et al.
Published: (2022-05-01)

Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics
by: Christoph Stein, et al.
Published: (2012-06-01)

The role of MSCs and CAR-MSCs in cellular immunotherapy
by: Lun Yan, et al.
Published: (2023-08-01)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024-12-01)

Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023
by: Wangshu Li, et al.
Published: (2024-12-01)

Diversity of immune checkpoints in cancer immunotherapy
by: Zhangyan Guo, et al.
Published: (2023-03-01)

Immunotherapeutic Development of a Tri-Specific NK Cell Engager Recognizing BCMA
by: Felix Oh, et al.
Published: (2023-06-01)

DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells in vitro: a proof-of-concept study
by: Chiara Focaccetti, et al.
Published: (2022-07-01)

Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer
by: Carlos Moreno, et al.
Published: (2022-06-01)

The innate defenders: a review of natural killer cell immunotherapies in cancer
by: Pablo Álvarez-Carrasco, et al.
Published: (2024-12-01)

NK cells in renal cell carcinoma and its implications for CAR-NK therapy
by: Xinwei Li, et al.
Published: (2025-02-01)

Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer
by: Yuankui Zhu, et al.
Published: (2025-02-01)

Natural killer cells in cancer immunotherapy
by: DanRu Wang, et al.
Published: (2024-07-01)

The roles of immune cells in Behçet’s disease
by: Dan Hu, et al.
Published: (2023-10-01)

Immunomodulatory roles of selenium nanoparticles: Novel arts for potential immunotherapy strategy development
by: Gengshi Chen, et al.
Published: (2022-07-01)

Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma
by: Jingjing Pu, et al.
Published: (2024-10-01)

CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review
by: Ler Yie Chan, et al.
Published: (2022-03-01)

Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights
by: Zuhui Pu, et al.
Published: (2023-11-01)